Standard BioTools (NASDAQ:LAB) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.03) by 133.33 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $20.104 million which missed the analyst consensus estimate of $20.805 million by 3.37 percent. This is a 52.09 percent decrease over sales of $41.962 million the same period last year.